Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low vs. high hemoglobin trigger for Transfusion in Vascular surgery (TV): a randomized clinical feasibility trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns

    Research output: Contribution to journalLetterResearchpeer-review

  4. Yet another susceptibility variant for ALL: what's next?

    Research output: Contribution to journalComment/debateResearchpeer-review

  5. A small change makes a big difference in Hodgkin lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Reliable cell and tissue morphology-based diagnosis of endemic Burkitt lymphoma in resource-constrained settings in Ghana

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Proteomic profiling identifies outcome-predictive markers in patients with peripheral T-cell lymphoma, not otherwise specified

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Rebecca A Luchtel
  • Surendra Dasari
  • Naoki Oishi
  • Martin Bjerregård Pedersen
  • Guangzhen Hu
  • Karen L Rech
  • Rhett P Ketterling
  • Jagmohan Sidhu
  • Xueju Wang
  • Ryohei Katoh
  • Ahmet Dogan
  • N Sertac Kip
  • Julie M Cunningham
  • Zhifu Sun
  • Saurabh Baheti
  • Julie C Porcher
  • Jonathan W Said
  • Liuyan Jiang
  • Stephen Jacques Hamilton-Dutoit
  • Michael Boe Møller
  • Peter Nørgaard
  • N Nora Bennani
  • Wee-Joo Chng
  • Gaofeng Huang
  • Brian K Link
  • Fabio Facchetti
  • James R Cerhan
  • Francesco d'Amore
  • Stephen M Ansell
  • Andrew L Feldman
View graph of relations

Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types. Although ALK-positive ALCLs consistently bear rearrangements of the ALK tyrosine kinase gene, ALK-negative ALCLs are clinically and genetically heterogeneous. About 30% of ALK-negative ALCLs have rearrangements of DUSP22 and have excellent long-term outcomes with standard therapy. To better understand this group of tumors, we evaluated their molecular signature using gene expression profiling. DUSP22-rearranged ALCLs belonged to a distinct subset of ALCLs that lacked expression of genes associated with JAK-STAT3 signaling, a pathway contributing to growth in the majority of ALCLs. Reverse-phase protein array and immunohistochemical studies confirmed the lack of activated STAT3 in DUSP22-rearranged ALCLs. DUSP22-rearranged ALCLs also overexpressed immunogenic cancer-testis antigen (CTA) genes and showed marked DNA hypomethylation by reduced representation bisulfate sequencing and DNA methylation arrays. Pharmacologic DNA demethylation in ALCL cells recapitulated the overexpression of CTAs and other DUSP22 signature genes. In addition, DUSP22-rearranged ALCLs minimally expressed PD-L1 compared with other ALCLs, but showed high expression of the costimulatory gene CD58 and HLA class II. Taken together, these findings indicate that DUSP22 rearrangements define a molecularly distinct subgroup of ALCLs, and that immunogenic cues related to antigenicity, costimulatory molecule expression, and inactivity of the PD-1/PD-L1 immune checkpoint likely contribute to their favorable prognosis. More aggressive ALCLs might be pharmacologically reprogrammed to a DUSP22-like immunogenic molecular signature through the use of demethylating agents and/or immune checkpoint inhibitors.

Original languageEnglish
JournalBlood
Volume132
Issue number13
Pages (from-to)1386-1398
Number of pages13
ISSN0006-4971
DOIs
Publication statusPublished - 27 Sep 2018

ID: 56605592